Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION AstraZeneca launches and prices a €750,000,000 7...
-
· Late-stage pipeline transformed well ahead of plan through increased R&D productivity, accelerated programmes and targeted business development; 14 potential new medicines in Phase III or...
-
Publication of Supplemental Prospectus Following a routine technical update in June 2014 of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following...
-
AMGEN AND ASTRAZENECA ANNOUNCE POSITIVE RESULTS FROM SECOND PIVOTAL PHASE III STUDY OF BRODALUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Brodalumab meets all primary and all key...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 10 November 2014, Luke Miels, EVP, Global Product and Portfolio Strategy, a person discharging managerial...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 10 November 2014, Luke Miels, EVP, Global Product and Portfolio Strategy, a person discharging managerial...
-
ASTRAZENECA TO DIVEST MYALEPT TO AEGERION AstraZeneca today announced that it has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for...
-
Intäkterna under tredje kvartalet uppgick till 6 542 MUSD, en ökning med 5 % i fasta valutakurser (CER), det tredje kvartalet i följd med intäktstillväxt, med starkt bidrag från tillväxtplattformarna...
-
AstraZeneca PLC THIRD Quarter AND NINE MONTHS Results 2014 London, 6 November 2014 Revenue in the third quarter was $6,542 million, up 5%* - third...
-
Tomorrow, Thursday, 6 November 2014, AstraZeneca will release third quarter and nine months results 2014 at 07:00 GMT. An analysts presentation of the third quarter and nine months results will...